MARKET

RVPHW

RVPHW

Reviva Pharmaceutcls Hldgs Inc
NASDAQ
0.6306
-0.0382
-5.71%
Closed 16:00 03/28 EDT
OPEN
0.7500
PREV CLOSE
0.6688
HIGH
0.7500
LOW
0.6000
VOLUME
21.04K
TURNOVER
0
52 WEEK HIGH
3.000
52 WEEK LOW
0.4085
MARKET CAP
--
P/E (TTM)
-0.3787
1D
5D
1M
3M
1Y
5Y
Reviva Pharmaceuticals Holdings, Inc. <RVPH.OQ> expected to post a loss of 35 cents a share - Earnings Preview
Reviva Pharmaceuticals Holdings, Inc. Expected to post a loss of 35 cents a share. The company is expected to show change in quarterly revenue when it reports results on March 28. The average analyst rating on the shares is "buy" and the median 12-month price target is $17.00.
Reuters · 2d ago
Weekly Report: what happened at RVPHW last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RVPHW last week (0311-0315)?
Weekly Report · 03/18 09:42
Weekly Report: what happened at RVPHW last week (0304-0308)?
Weekly Report · 03/11 09:41
Weekly Report: what happened at RVPHW last week (0226-0301)?
Weekly Report · 03/04 09:42
Weekly Report: what happened at RVPHW last week (0219-0223)?
Weekly Report · 02/26 09:46
Weekly Report: what happened at RVPHW last week (0212-0216)?
Weekly Report · 02/19 09:46
Weekly Report: what happened at RVPHW last week (0205-0209)?
Weekly Report · 02/12 09:42
More
About RVPHW
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Webull offers Reviva Pharmaceuticals Holdings, Inc. stock information, including NASDAQ: RVPHW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVPHW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVPHW stock methods without spending real money on the virtual paper trading platform.